Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age | Zendy

Denise L. Jacobson | Zendy; Jane C. Lindsey | Zendy; Catherine M. Gordon | Zendy; Rohan Hazra | Zendy; Hans Spiegel | Zendy; Flávia V. Ferreira | Zendy; Fabiana Amaral | Zendy; Jesica PaganoTherrien | Zendy; Aditya H. Gaur | Zendy; Kathy George | Zendy; Jane E. Benson | Zendy; George K. Siberry | Zendy

Open Access

Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age

Author(s) -

Denise L. Jacobson,

Jane C. Lindsey,

Catherine M. Gordon,

Rohan Hazra,

Hans Spiegel,

Flávia V. Ferreira,

Fabiana Amaral,

Jesica PaganoTherrien,

Aditya H. Gaur,

Kathy George,

Jane E. Benson,

George K. Siberry

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz957

Subject(s) - medicine , bone mineral , osteoporosis , placebo , bisphosphonate , vitamin d and neurology , pediatrics , bone density , confidence interval , alternative medicine , pathology

Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate therapy has been shown to reduce fractures in adults with osteoporosis, but has not been formally studied in youths living with HIV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research